Drug intelligence / Profile preview

TNK01

Development stage: Preclinical
Lead developer: SynoCare
Modality: Small Molecules

Overview

TNK01 is a preclinical-stage small molecule therapeutic being developed by SynoCare for the treatment of solid tumors. The drug is part of a pipeline focused on synthetic lethality, a strategy that targets specific genetic vulnerabilities in cancer cells to induce cell death while minimizing impact on healthy tissue. While the exact molecular target (designated by the sponsor as TNK01XX) is currently undisclosed, TNK01 represents one of the lead candidates in SynoCare's oncology portfolio utilizing this platform.

Targets

TNK01XX (TNK01XX)

Beyond the preview

Go deeper on TNK01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNK01.

Explore the full profile